Intravitreal aflibercept therapy in eyes with chronic central serous chorioretihopathy: Short term results

Daruich, 2015, Central serous chorioretinopathy: recent findings and new physiopathology hypothesis, Prog Retin Eye Res, 48, 82, 10.1016/j.preteyeres.2015.05.003 Salehi, 2015, Interventions for central serous chorioretinopathy: a network meta-analysis, Cohrane Databese Syst Rev, 12, CD011841 Liegl, 2014, Central serous chorioretinopathy, Ophthalmologica, 232, 65, 10.1159/000360014 Nicholson, 2013, Central serous chorioretinopathy: update on pathophysiology and treatment, Surv Ophthalmol, 58, 103, 10.1016/j.survophthal.2012.07.004 Gemenetzi, 2010, Central serous chorioretinopathy: an update on pathogenesis and treatment, Eye (Lond), 24, 1743, 10.1038/eye.2010.130 Wong, 2016, Central serous chorioretinopathy: what we have learnt so far, Acta Ophthalmol, 94, 321, 10.1111/aos.12779 Iacono, 2015, Central serous chorioretinopathy treatments: a mini review, Ophthalmic Res, 55, 76, 10.1159/000441502 Robertson, 1983, Direct, indirect and sham laser photocoagulation in the management of central serous chorioretinopathy, Am J Ophthalmol, 95, 457, 10.1016/0002-9394(83)90265-9 Chan, 2008, Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial, Ophthalmology, 115, 1756, 10.1016/j.ophtha.2008.04.014 Ma, 2014, System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy, Acta Ophthalmol, 92, 594, 10.1111/aos.12482 Weis, 2005, Pathophysiological consequences of VEGF-induced vascular permeability, Nature, 437, 497, 10.1038/nature03987 Seong, 2009, Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect, Ophthalmologica, 223, 343, 10.1159/000224782 Tekin, 2018, Intravitreal bevacizumab and ranibizumab in the treatment of acute central serous chorioretihopathy: a single center retrospective study, Semin Ophthalmol, 33, 265 Mehany, 2010, Role of avastin in management of central serous chorioretinopathy, Saudi J Ophthalmol, 24, 69, 10.1016/j.sjopt.2010.03.002 Inoue, 2011, Results of one-year follow-up examinations after intravitreal bevazicumab administration for chronic central serous chorioretinopathy, Ophthalmologica, 225, 37, 10.1159/000314709 Stewart, 2008, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol, 92, 667, 10.1136/bjo.2007.134874 Gawęcki, 2017, Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser, Graefes Arch Clin Exp Ophthalmol, 255, 2299, 10.1007/s00417-017-3783-x Leaver, 1979, Argon laser photocoagulation in the treatment of central serous retinopathy, Br J Ophthalmol, 63, 674, 10.1136/bjo.63.10.674 Erikitola, 2014, Photodynamic therapy for central serous chorioretinopathy, Eye (Lond), 28, 944, 10.1038/eye.2014.134 Bosquet, 2013, Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretnioapthy: a pilot study, Retina, 33, 2096, 10.1097/IAE.0b013e318297a07a Ghadiali, 2016, Central serous chorioretinopathy treated with mineralocorticoid antagonists: a one-year pilot study, Retina, 36, 611, 10.1097/IAE.0000000000000748 Guyer, 1994, Digital indocyanine green videoangiography of central serous chorioretinopathy, Arch Ophthalmol, 112, 1057, 10.1001/archopht.1994.01090200063023 Stanga, 2003, Indocyanine green angiography in chorioretinal diseases. Indications and interpretation: an evidence-based update, Ophthalmology, 110, 15, 10.1016/S0161-6420(02)01563-4 Imamura, 2009, Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy, Retina, 29, 1469, 10.1097/IAE.0b013e3181be0a83 Chung, 2013, Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopthy: meta analysis and review, Eye (Lond), 27, 1339, 10.1038/eye.2013.236 Bae, 2011, A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy, Am J Ophthalmol, 152, 784, 10.1016/j.ajo.2011.04.008 Lim, 2010, Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy, Retina, 30, 1465, 10.1097/IAE.0b013e3181d8e7fe Zhang, 2009, VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis, Proc Natl Acad Sci U S A, 106, 6152, 10.1073/pnas.0813061106 Browning, 2012, Aflibercept for age-related macular degeneration: a game-changer or quiet addition?, Am J Ophthalmol, 154, 222, 10.1016/j.ajo.2012.04.020 Pitcher, 2015, A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study, Br J Ophthalmol, 99, 848, 10.1136/bjophthalmol-2014-306018 Teussink, 2015, OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy, Invest Ophthalmol Vis Sci, 56, 5229, 10.1167/iovs.15-17140 Costanzo, 2015, Optical coherence tomography angiography in central serous chorioretinopathy, J Ophthalmol, 2015, 134783, 10.1155/2015/134783 Quaranta-el Maftouhi, 2015, Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography, Am J Ophthalmol, 160, 581, 10.1016/j.ajo.2015.06.016